DailyMed Lists a Two-Part Cold Relief Kit With Separate Daytime and Nighttime Formulas
DailyMed’s updated label for MAXIMUM STRENGTH DAYTIME NIGHTTIME brings together two familiar over-the-counter approaches to upper respiratory symptom control: a daytime caplet built around acetaminophen and guaifenesin, and a nighttime caplet combining acetaminophen, dextromethorphan, and triprolidine. The structure of the kit is clinically familiar, but the label is unusually explicit about the risks that come with multi-symptom self-treatment, especially when acetaminophen is present in both components.
The daytime tablet is designed for fever, pain, and mucus. The nighttime tablet shifts the focus toward cough suppression, allergic or histaminic symptoms, and sleep disruption. In practice, this split reflects a common therapeutic logic: patients with colds do not need the same symptom profile covered around the clock, and a sedating antihistamine is far more defensible at bedtime than during the workday. The label takes that logic one step further by making the dosing ceilings different for each component, a reminder that symptom control and hepatic safety have to be balanced from the first dose.
Acetaminophen Drives the Main Safety Constraint in Both Products
Each daytime caplet contains 325 mg of acetaminophen and 200 mg of guaifenesin. Each nighttime caplet contains 325 mg of acetaminophen, 10 mg of dextromethorphan hydrobromide, and 1.25 mg of triprolidine hydrochloride. The shared ingredient is the one most likely to shape bedside counseling. Acetaminophen is effective for minor aches, sore throat pain, and fever, but the label repeatedly warns that excessive total intake can cause severe liver damage. The daytime product caps use at 12 caplets in 24 hours; the nighttime product caps use at 8 caplets in 24 hours.
This difference matters because the same patient may reach for other acetaminophen-containing remedies without realizing they are stacking doses. A separate over-the-counter cold tablet, a headache product, or a prescription analgesic can push total exposure into unsafe territory quickly. The package also flags three or more alcoholic drinks daily as a liver-risk amplifier, which is exactly the kind of real-world detail that determines whether a seemingly ordinary self-care plan becomes a toxic one.
A single acetaminophen ingredient can determine the entire safety envelope.
Daytime Formula Aims at Productive Cough and Febrile Discomfort
The daytime caplet combines acetaminophen with guaifenesin, an expectorant intended to loosen phlegm and thin bronchial secretions. That pairing is clinically coherent for patients whose cough is productive rather than dry. By reducing mucus viscosity, guaifenesin may make coughs more effective rather than merely less frequent, which is an important distinction in uncomplicated colds and flu-like illness. The label also lists temporary relief of headache, sore throat, and minor aches and pains, alongside fever reduction.
The product is limited to adults and children 12 years of age and older, with instructions to take 2 caplets every 4 hours and to avoid exceeding 12 caplets in 24 hours. The label also advises against use in children under 12 years of age. This is standard for many combination cold products, but the practical consequence is easy to miss: the daytime formulation is not a benign “all symptoms” tablet. It is a narrow, dose-bounded product for common cold and influenza symptoms, not a substitute for evaluation when cough or fever persists.
The label directs patients to stop use and seek medical advice if pain or cough lasts more than 7 days, if fever lasts more than 3 days, or if redness or swelling appears. Severe sore throat lasting beyond 2 days, especially when accompanied by fever, rash, nausea, or vomiting, also warrants prompt medical assessment. Those warnings separate routine viral illness from conditions that may require a different diagnosis or a different therapy altogether.
Nighttime Formula Adds Cough Suppression and Sedation Risk
The nighttime caplet is built around dextromethorphan, a cough suppressant, and triprolidine, an antihistamine. The clinical purpose is obvious from the label itself: control cough enough to allow sleep, while also addressing runny nose, sneezing, itchy nose or throat, and watery eyes due to hay fever. For a patient awake at night with a dry, irritating cough, that can be useful. Triprolidine’s antihistamine effect also explains the predictable warning for marked drowsiness.
The label explicitly warns against use with monoamine oxidase inhibitors, and for 2 weeks after stopping them. It also asks patients to consult a clinician before use if they have glaucoma, trouble urinating from an enlarged prostate, breathing problems such as emphysema or chronic bronchitis, or persistent cough related to smoking, asthma, or emphysema. Those cautions reflect the pharmacology of an older sedating antihistamine class, where anticholinergic effects can aggravate urinary retention, ocular pressure concerns, or lower respiratory disease symptom patterns.
Alcohol, sedatives, and tranquilizers may increase drowsiness. The label also warns that excitability may occur, especially in children, another reminder that sedating antihistamines can produce paradoxical responses in younger patients. Adults and children 12 years of age and over are instructed to take 2 caplets every 4 hours, with a ceiling of 8 caplets in 24 hours. As with the daytime product, children under 12 years of age are told not to use it.
Label Warnings Point to Liver Risk, Drug Interactions, and the Need for Triage
The presence of warfarin in the warning section is a standard but important signal to patients and clinicians who may otherwise view OTC cold therapy as low stakes. The label advises asking a doctor or pharmacist before use if taking warfarin. It also advises medical input for people with liver disease, chronic cough, cough with excessive mucus, or, in the nighttime formulation, glaucoma and urinary difficulty. Pregnancy and breastfeeding require consultation with a health professional before use.
The overdose warning is blunt and clinically appropriate: taking more than the recommended dose may cause liver damage, and quick medical attention is critical even when symptoms are not yet obvious. The label directs patients to Poison Control at 1-800-222-1222 in the event of overdose. That advice deserves attention because acetaminophen toxicity can remain clinically silent long enough to delay care, while liver injury continues to evolve.
The kit’s packaging details also reinforce that this is a monograph OTC drug product rather than a bespoke prescription combination. The daytime component appears as a 2 in 1 carton with blister packs, while the nighttime component is packaged separately in its own blister configuration. The label lists the product under OTC Monograph Drug M012 and identifies Kroger Company as packager.
For everyday practice, the label’s most consequential message is straightforward: symptom relief is available, but the margin for error is narrow when acetaminophen is embedded in more than one dose form. Patients may buy a cold kit for convenience and end up with overlapping exposure unless they read both panels carefully. The label leaves little room for improvisation, and that is the right posture for a product built to be helpful, but only within tightly defined limits.